Loading...
NPI 1316332455 · Baltimore, MD · Retina Specialist (Ophthalmology) Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
David Dao is a retina specialist (ophthalmology) physician provider located in Baltimore, Maryland. This profile covers 22 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | David Dao |
| Address | 9114 Philadelphia Rd Ste 310 |
| City | Baltimore |
| State | MD |
| ZIP | 21237 |
| Taxonomy | Retina Specialist (Ophthalmology) Physician |
| NPI Enumerated | April 6, 2015 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $3.8M |
| Medicaid | $260 |
DAVID DAO is a Retina Specialist (Ophthalmology) Physician with an NPI enumerated on 2015-04-06 (~11 years ago), indicating more than a decade of billing history. The Medicare portfolio ($3.8M total Medicare revenue) is large relative to the provider's minimal Medicaid footprint, consistent with an established, specialty retina practice concentrated on Medicare beneficiaries.
Revenue is highly concentrated in intravitreal injectable drugs: the top three Medicare codes by revenue (J2777, J0178, J2778) account for 80.2% of this provider's total Medicare revenue. J2777 alone generated $1.8M (47.9% of Medicare revenue) from 63.3K claims at a $29 avg paid/claim, while J0178 produced $637.1K ($672 avg/claim) and J2778 produced $597.3K ($181 avg/claim), signaling a business model built around high-volume anti-VEGF and related intravitreal therapies.
Beyond drug codes, the claims mix shows frequent supportive procedures and diagnostics consistent with a procedure-heavy retina clinic: 67028 (intravitreal injection procedure) generated $214.1K and ranks #340 of 4255 (92th percentile; notably above typical national volume), and 92134 (retinal imaging) generated $97.8K and ranks #424 of 26868 (98th percentile; extreme outlier). These procedure and imaging volumes align with sustained follow-up and monitoring typical in retinal disease management.
The provider shows unusually high E/M billing volume for established visits: 99214 appears as 2K claims with $213.2K revenue and ranks #1377 of 479517 providers nationally (100th percentile; extreme outlier, far above typical national volume). This suggests heavy utilization of moderate-complexity office visits alongside injection and imaging services, implying significant clinic throughput and follow-up intensity.
Competitive standing is mixed by code: for Medicare J2777 ranks #63 of 2039 (97th percentile; notably above typical national volume), indicating a strong national position for faricimab administration; by contrast J0178 ranks #1335 of 3204 (58th percentile; typical, unremarkable volume) and J2778 ranks #95 of 1208 (92th percentile; typical, unremarkable volume). Together these rankings imply the provider is a major national participant for faricimab while holding more typical volumes for other biologic injectables.
Medicaid activity is effectively negligible compared with Medicare: total Medicaid revenue is reported as $261 while the Medicaid top code file records 92201 at $266 and 19 claims (100.0% of this provider's total Medicaid revenue), ranked #15 of 16 in-state (7th percentile; typical, unremarkable volume). The presence of a single small Medicaid code suggests the provider is functionally Medicare-dominant with almost no meaningful Medicaid revenue exposure.
The billing mix highlights differential reimbursement dynamics across injectables: J2777 produced $1.8M from a very high claim count at a $29 avg paid/claim, whereas J0178 produced $637.1K at a $672 avg paid/claim and J2778 produced $597.3K at a $181 avg paid/claim. This pattern indicates the practice delivers large volumes of low-unit reimbursement drug administrations (faricimab) while also using higher-paid agents less frequently, which has implications for drug procurement, inventory management, and revenue-per-service planning.
Top-code concentration is pronounced and operationally meaningful: the top three Medicare codes account for 80.2% of Medicare revenue and the Medicaid top three account for 100.0% of Medicaid revenue, underscoring reliance on a narrow set of services. For payers and network decision-makers, this profile identifies DAVID DAO as a procedure- and injection-focused retina provider with concentrated revenue risk tied to injectable drug utilization and follow-up visit volume.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
22 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 63,300 | $30 | $1.8M |
| J0178 | Injection, aflibercept, 1 mg | 950 | $670 | $637.1K |
| J2778 | Injection, ranibizumab, 0.1 mg | 3,300 | $180 | $597.3K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 2,120 | $100 | $214.1K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,970 | $110 | $213.2K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 2,960 | $30 | $97.8K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 660 | $100 | $65.1K |
| 92235 | The provider uses a special dye, fluorescein that causes the blood vessels in the one or both eyes to stand out in photographic images taken with the use of multiframe timing, or serial images, taken… | 370 | $110 | $41.9K |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | 210 | $160 | $33K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 400 | $80 | $30.6K |
Showing 1–10 of 22
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 22 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
22 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 49 | 100 | 950 | $690 | $887.3K |
| J2777 | 4 | 70 | 8,520 | $30 | $487.3K |
| J2778 | 4 | 50 | 650 | $180 | $207.8K |
| 67028 | 19 | 120 | 700 | $100 | $101.5K |
| J7312 | 16 | 20 | 270 | $160 | $53.1K |
| 92014 | 138 | 620 | 210 | $90 | $44K |
| 99214 | 65 | 10,270 | 150 | $90 | $24.1K |
| 92235 | 12 | 90 | 70 | $110 | $19.5K |
| 92134 | 26 | 490 | 110 | $30 | $17.3K |
| 92012 | 327 | 360 | 100 | $70 | $14.4K |
Showing 1–10 of 22
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 92201 | The provider performs an extended ophthalmoscopy, typically with an indirect ophthalmoscope which utilizes a bright light and a hand–held indirect lens rather than the common hand–held one–piece… | 20 | $10 | $270 |
How this provider's Medicaid billing volume and revenue compare to other Maryland providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Maryland median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 92201 | The provider performs an extended ophthalmoscopy, typically with an indirect ophthalmoscope which utilizes a bright light and a hand–held indirect lens rather than the common hand–held one–piece… | 15 | 20 | 110 | $20 | $31.2K |
Other providers in the same ZIP code as David Dao, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.